Cardiovascular Disease Prevention
14
6
6
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 14 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (14)
INTEGRATE-RX: Integrating Clinical Pharmacists in HIV Care to Mitigate Last-Mile Challenges and Reduce Cardiovascular Disease Burden
Effects of a Smartphone-Supported Daily Walking Intervention on Psychological Well-Being and Body Composition in Adults With Cardiometabolic Disease
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases
Monitoring and Guidance of Physical Activity During the Maintenance Phase of Cardiac Rehabilitation: the Antwerp Activity Index
Digital Prevention Program With Telephonic Coaching
Assessment and Prediction of Cardiovascular Health and Disease Risk Using Wearable Biometrics.
Akershus Cardiac Examination (ACE) 5 Study
Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway
Family Matters Intervention
Preventative Screening and Health Coaching in a Food Insecure Population
Real-World Evaluation of a Digitally Enabled Cardiac Rehabilitation Program
Community Pharmacist Intervention to Enhance Adherence in Cardiovascular Drug Initiators
Impact of a Nutritional Supplement on Metabolic Health